Penumbra, Inc. (PEN) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
PEN Revenue Growth
Revenue Breakdown (FY 2022)
PEN's revenue distribution by segment and geography for fiscal year 2022
By Product/Segment
By Geography
PEN Revenue Analysis (2014–2025)
As of May 8, 2026, Penumbra, Inc. (PEN) generated trailing twelve-month (TTM) revenue of $1.45 billion, reflecting strong growth of +15.6% year-over-year. The most recent quarter (Q1 2026) recorded $374.8 million in revenue, down 2.8% sequentially.
Looking at the longer-term picture, PEN's 5-year compound annual growth rate (CAGR) stands at +20.2%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $1.40 billion in 2025, representing a new all-time high.
Revenue diversification analysis shows PEN's business is primarily driven by Peripheral Vascular (59%), and Neuro (41%). With over half of revenue concentrated in Peripheral Vascular, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including ISRG (+21.4% YoY), NVCR (+8.5% YoY), and NVST (+12.1% YoY), PEN has underperformed the peer group in terms of revenue growth. Compare PEN vs ISRG →
PEN Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| PENCurrent | $1.5B | +15.6% | +20.2% | 13.5% | |
 ISRG | $10.1B | +21.4% | +18.2% | 29.3% | |
 NVCR | $655M | +8.5% | +5.8% | -23.5% | |
 NVST | $2.7B | +12.1% | +7.1% | 8.3% | |
 INVA | $425M | +13.6% | +4.8% | 38.5% | |
 SYK | $25.1B | +11.2% | +11.8% | 19.5% |
PEN Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $1.40B | +17.5% | $942.4M | 67.1% | $189.2M | 13.5% |
| 2024 | $1.19B | +12.9% | $755.0M | 63.2% | $9.3M | 0.8% |
| 2023 | $1.06B | +25.0% | $682.6M | 64.5% | $73.6M | 6.9% |
| 2022 | $847.1M | +13.3% | $535.2M | 63.2% | $6.1M | 0.7% |
| 2021 | $747.6M | +33.4% | $475.4M | 63.6% | $-7,501,000 | -1.0% |
| 2020 | $560.4M | +2.4% | $338.2M | 60.3% | $-38,942,000 | -6.9% |
| 2019 | $547.4M | +23.0% | $372.0M | 68.0% | $47.5M | 8.7% |
| 2018 | $444.9M | +33.3% | $292.5M | 65.7% | $-852,000 | -0.2% |
| 2017 | $333.8M | +26.8% | $217.1M | 65.1% | $1.2M | 0.3% |
| 2016 | $263.3M | +41.5% | $170.8M | 64.9% | $-1,350,000 | -0.5% |
Full PEN Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See PEN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PEN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PEN vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonPEN — Frequently Asked Questions
Quick answers to the most common questions about buying PEN stock.
Is PEN's revenue growth accelerating or slowing?
PEN revenue is accelerating at +15.6% year-over-year, exceeding the 5-year CAGR of +20.2%. TTM revenue reached $1.5B. Growth momentum has increased versus prior periods.
What is PEN's long-term revenue growth rate?
Penumbra, Inc.'s 5-year revenue CAGR of +20.2% reflects the sustained expansion pattern. Current YoY growth of +15.6% is above this long-term average.
How is PEN's revenue distributed by segment?
PEN reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.